West Enclave Merger Corp. 10-Q Summary (Q2 2026)
Business Context and Reporting Period
West Enclave Merger Corp. is a Cayman Islands exempted company formed as a Special Purpose Acquisition Company (SPAC) to effect a business combination. The reporting period covers the quarter and six months ended June 30, 2026. The Company consummated its Initial Public Offering (IPO) on May 1, 2026, and fully exercised the underwriters' over-allotment option on May 6, 2026. As of the reporting date, the Company has not commenced any operating activities; all activity relates to formation, the IPO, and identifying a target business.
Key Financial Metrics
| Metric | Value (Six Months Ended June 30, 2026) |
|---|---|
| Net Income | $469,457 |
| Operating Loss | $(181,994) |
| Interest Income (Trust Account) | $651,451 |
| Total Assets | $117,806,772 |
| Cash and Marketable Securities (Trust) | $116,801,451 |
| Cash (Outside Trust) | $879,639 |
| Working Capital | $823,944 |
| Total Liabilities | $430,544 |
| Ordinary Shares Subject to Redemption | 11,500,000 shares ($116,801,451) |
| Net Cash Provided by Financing | $117,264,320 |
Material Changes vs. Prior Period
The Company was incorporated on December 9, 2025. Consequently, there are no comparative financial statements for the prior year. The balance sheet reflects a transition from a pre-IPO shell company with minimal assets ($454,470 as of Dec 31, 2025) to a post-IPO entity with significant trust assets. Key changes include:
- Capital Raise: Gross proceeds of $115,000,000 from the IPO and $4,662,500 from private placements.
- Trust Account: Establishment of a Trust Account holding $116,150,000 initially, growing to $116,801,451 due to interest income.
- Equity Structure: Issuance of 11,500,000 Public Shares (subject to redemption) and 4,549,583 non-redeemable ordinary shares (Founder and Private Placement shares).
- Debt: Incurrence of a $287,500 loan from EarlyBirdCapital (EBC) to fund the Trust Account.
Outlook, Risks, and Management Commentary
Outlook and Liquidity: Management believes the Company has sufficient funds to finance working capital needs for at least one year from the date of issuance. The Company has 21 months from the IPO closing (May 2026) to consummate a business combination. If no combination occurs, the Company will liquidate and redeem public shares.
Contingencies and Risks:
- Business Combination Risk: There is no assurance the Company will successfully complete a business combination.
- Redemption Risk: Public shareholders may redeem shares for a pro-rata portion of the Trust Account, potentially reducing funds available for the transaction.
- Deferred Fees: The Company owes a deferred underwriting fee of 3.5% of gross proceeds (approx. $4,025,000) payable only upon consummation of a business combination.
- Related Party Loans: The Sponsor and affiliates may provide working capital loans up to $1,500,000, convertible into private placement units.
Unusual Items: The net income is entirely non-operating, derived from interest earned on the Trust Account. The Company incurred $3,159,249 in transaction costs related to the IPO.
Investor Verification Checklist
- Trust Account Balance: Verify the current balance of $116,801,451 and the per-share redemption value of approximately $10.16.
- Combination Deadline: Confirm the 21-month deadline to complete a business combination (approx. February 2028).
- Deferred Underwriting Fee: Note the contingent liability of ~$4.0 million payable only upon a successful merger.
- Related Party Exposure: Review the $287,500 EBC loan and the $10,000 monthly administrative fee payable to the Sponsor.
- Over-Allotment Status: Confirm that the 1,500,000 over-allotment units were fully exercised on May 6, 2026, removing forfeiture risk on founder shares.